超300%！688336，净利大幅预增

Company Overview - Sanofi Guojian (688336) announced its 2025 annual performance forecast, expecting revenue of approximately 4.2 billion yuan, a year-on-year increase of 251.76%, and a net profit attributable to shareholders of around 2.9 billion yuan, reflecting a growth of 311.35% compared to the previous year [2] - The significant increase in performance is attributed to a major collaboration with Pfizer, which involved a licensing fee payment of approximately 2.89 billion yuan for the 707 project, leading to substantial growth in revenue and net profit [2] Business Development Transactions - In May 2025, Sanofi Guojian, along with its subsidiaries, granted Pfizer exclusive rights for the development, production, and commercialization of the 707 project, a bispecific antibody product targeting both PD-1 and VEGF [5] - According to the agreement, Pfizer will pay a non-refundable and non-deductible upfront fee of $1.25 billion, along with potential milestone payments up to $4.8 billion and royalties based on annual net sales in the licensed area [5] Industry Trends - The record-breaking upfront payment of $1.25 billion for this transaction highlights the strength of Chinese innovative drugs and reflects a reassessment of the value of domestic innovations by international giants [7] - In 2025, China approved 76 innovative drugs, surpassing the 48 approved in 2024, marking a historical high. The total value of licensing transactions for innovative drugs exceeded $130 billion, with over 150 deals, significantly higher than the $51.9 billion and 94 deals in 2024 [7] - The bispecific antibody targeting PD-1/VEGF represents a new class of cancer therapies, potentially becoming a cornerstone for next-generation cancer treatments, with several domestic companies engaging in similar business development transactions [7]